Study on Covishield, Covaxin antibody response is limited: Bharat Biotech

Raches Ella, project lead, Covid-19 vaccines at the firm says he is surprised that media and researchers are drawing conclusions based on non-peer reviewed work

After a study by a group of doctors concluded that Indian health care workers administered Covishield have shown better antibody response than Covaxin recipients, senior officials at Bharat Biotech said that the study had limitations.

Raches Ella, project lead, Covid-19 vaccines at Bharat Biotech said in a series of tweets that he was ‘surprised’ that media and researchers were drawing conclusions based on non-peer reviewed work.

Ella went on to add the limitations he felt that study had. “Limitation 1: Spike-based IgG's are not appropriate when evaluating Covaxin, which induces broad antibody responses to Spike, N, and M. Recommend live